Lupin Ltd

NSE: LUPIN · BSE: 500257 · Pharmaceuticals & Biotechnology · 57 announcements

Lupin Ltd news stories on ALFA NewsRead the news →

Share price: ₹2,006.90
Market cap: ₹91,774 Cr
Revenue (annual): ₹27,958 Cr
Net profit (annual): ₹5,333 Cr
P/E (TTM): 16.6×Sector 47.4×
Promoter holding: 46.85%-0.01% QoQ
FII holding: 22.42%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Employee Stock Options 3 Annual General Meeting 3 Product Launch 2 Other Announcement 2 Financial Results 2 Earnings Call 2 Business Update 2 Regulatory Approval 1 Partnership 1 Merger & Restructuring 1 Management Change 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

20 Aug 2026 10:46 IST NSE

PartnershipAlfa Alert

Lupin Partnership

Lupin Limited's subsidiary VISUfarma B.V. signed an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ in Europe. The deal includes potential consideration of €75 million.

Value: ₹832.5 Cr
Execution: Initial term until 20th anniversary of first commercial sale

Read the story on ALFA News Read the filing ↗